BNOX
Bionomics Limited [BNOX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BNOX Stock Summary
Top 10 Correlated ETFs
BNOX
Top 10 Correlated Stocks
BNOX
In the News
BNOX Financial details
Company Rating
Neutral
Market Cap
10.64M
Income
-37.94M
Revenue
4.6M
Book val./share
2.09
Cash/share
1.07
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
12 Apr 2024
P/E
-0.61
Forward P/E
-
PEG
-0.07
P/S
23.24
P/B
0.49
P/C
0.92
P/FCF
-1.39
Quick Ratio
4.58
Current Ratio
4.87
Debt / Equity
0.04
LT Debt / Equity
-
-
-
EPS (TTM)
-4.77
EPS next Y
-
EPS next Q
-
EPS this Y
4.42%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
0.55%
Revenue last 5Y
-39.11%
Revenue Q/Q
-71.26%
EPS Q/Q
-6.78%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-50%
Inst Own
20.57%
Inst Trans
5.92%
ROA
-62%
ROE
-112%
ROC
-0.61%
Gross Margin
-1265%
Oper. Margin
-3649%
Profit Margin
-4088%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.87-6.41
52W High
-
52W Low
-
RSI
41
Rel Volume
0.08
Avg Volume
192.45K
Volume
16.34K
Perf Week
-2.01%
Perf Month
-16.25%
Perf Quarter
-62.6%
Perf Half Y
-77.88%
-
-
-
-
Beta
-0.092
-
-
Volatility
0.02%, 0.06%
Prev Close
2.17%
Price
0.9799
Change
4.24%
BNOX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
| Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.79 | 0.68 | 0.16 | 0.69 | 0.05 | |
| Net income per share | -2.53 | -1.33 | -1.51 | -2.49 | -2.6 | |
| Operating cash flow per share | -3.79 | -0.89 | -1.3 | -2.49 | -1.74 | |
| Free cash flow per share | -3.81 | -0.89 | -1.3 | -2.49 | -1.74 | |
| Cash per share | 3.53 | 1.04 | 5.01 | 3.83 | 1.49 | |
| Book value per share | 4.01 | 2.89 | 8.24 | 6.5 | 2.71 | |
| Tangible book value per share | -2.22 | -2.73 | 4.37 | 3.91 | 0.89 | |
| Share holders equity per share | 4.01 | 2.89 | 8.24 | 6.5 | 2.71 | |
| Interest debt per share | 4.44 | 2.78 | 0.03 | 0.02 | 0.01 | |
| Market cap | 42.56M | 44.59M | 63.83M | 42.25M | 17.95M | |
| Enterprise value | 45.59M | 49.85M | 43.11M | 19.55M | 6.15M | |
| P/E ratio | -5.83 | -11.1 | -9.79 | -2.81 | -0.85 | |
| Price to sales ratio | 8.23 | 21.59 | 91.71 | 10.11 | 41.49 | |
| POCF ratio | -3.89 | -16.55 | -11.29 | -2.81 | -1.26 | |
| PFCF ratio | -3.87 | -16.52 | -11.29 | -2.81 | -1.26 | |
| P/B Ratio | 3.67 | 5.09 | 1.79 | 1.08 | 0.81 | |
| PTB ratio | 3.67 | 5.09 | 1.79 | 1.08 | 0.81 | |
| EV to sales | 8.82 | 24.14 | 61.94 | 4.68 | 14.22 | |
| Enterprise value over EBITDA | -5.79 | -11.91 | -6.16 | -1.7 | -0.34 | |
| EV to operating cash flow | -4.17 | -18.51 | -7.63 | -1.3 | -0.43 | |
| EV to free cash flow | -4.14 | -18.47 | -7.62 | -1.3 | -0.43 | |
| Earnings yield | -0.17 | -0.09 | -0.1 | -0.36 | -1.18 | |
| Free cash flow yield | -0.26 | -0.06 | -0.09 | -0.36 | -0.79 | |
| Debt to equity | 1.11 | 0.96 | 0 | 0 | 0.01 | |
| Debt to assets | 0.34 | 0.35 | 0 | 0 | 0 | |
| Net debt to EBITDA | -0.38 | -1.26 | 2.96 | 1.97 | 0.66 | |
| Current ratio | 1.82 | 1.01 | 13.1 | 12.46 | 4.87 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 1.5 | 0.55 | 0.87 | 1 | 0.67 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.91 | 1.23 | 4.71 | 1.22 | 13.29 | |
| Research and developement to revenue | 1.65 | 1.95 | 6.21 | 2.64 | 30.19 | |
| Intangibles to total assets | 0.48 | 0.71 | 0.41 | 0.35 | 0.52 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.01 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.07 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0.01 | 0.02 | 1.41 | 0.47 | 2.93 | |
| Graham number | 15.1 | 9.29 | 16.7 | 19.07 | 12.58 | |
| ROIC | -0.37 | -0.31 | -0.22 | -0.31 | -0.83 | |
| Return on tangible assets | -0.37 | -0.59 | -0.27 | -0.51 | -1.54 | |
| Graham Net | -5.27 | -3.92 | 3.88 | 3.07 | 0.7 | |
| Working capital | 7.95M | 41.96K | 21.42M | 26.55M | 10.63M | |
| Tangible asset value | -6.41M | -8.25M | 18.93M | 23.62M | 7.23M | |
| Net current asset value | -8.44M | -9.28M | 18.19M | 23.07M | 6.82M | |
| Invested capital | 1.11 | 0.96 | 0 | 0 | 0.01 | |
| Average receivables | 493.1K | 290.54K | 78.37K | 2.4M | 2.55M | |
| Average payables | 1.76M | 857.47K | 820.99K | 923.15K | 1.22M | |
| Average inventory | 414.64K | 233.27K | 1.06 | -2.33M | -2.55M | |
| Days sales outstanding | 40.17 | 2.14 | 75.86 | 407.3 | 360.89 | |
| Days payables outstanding | 36.19 | 79.01 | 65.16 | 35.52 | 38.38 | |
| Days of inventory on hand | 20 | 0 | 0 | -154.16 | -11.95 | |
| Receivables turnover | 9.09 | 170.48 | 4.81 | 0.9 | 1.01 | |
| Payables turnover | 10.09 | 4.62 | 5.6 | 10.28 | 9.51 | |
| Inventory turnover | 18.25 | 3.56M | 4.32M | -2.37 | -30.54 | |
| ROE | -0.63 | -0.46 | -0.18 | -0.38 | -0.96 | |
| Capex per share | -0.02 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q2
| Metric | History | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.02 | 0.69 | 0.01 | 0.04 | 0.01 | |
| Net income per share | -1.7 | -1.02 | -1.47 | -1.18 | -1.1 | |
| Operating cash flow per share | -1.67 | -1.05 | -0.82 | -0.93 | 0 | |
| Free cash flow per share | -1.67 | -1.05 | -0.82 | -0.93 | 0 | |
| Cash per share | 5.26 | 3.94 | 2.79 | 1.38 | 1.07 | |
| Book value per share | 7.85 | 6.69 | 4.33 | 2.5 | 2.09 | |
| Tangible book value per share | 4.94 | 4.02 | 2.29 | 0.82 | 0.54 | |
| Share holders equity per share | 7.85 | 6.69 | 4.33 | 2.5 | 2.09 | |
| Interest debt per share | 0.02 | 0.02 | 0.01 | 0.01 | 0.09 | |
| Market cap | 70.01M | 41.08M | 34.89M | 19.39M | 14.04M | |
| Enterprise value | 41.25M | 18.38M | 14.41M | 7.59M | 4.98M | |
| P/E ratio | -1.85 | -1.71 | -0.79 | -0.47 | -0.34 | |
| Price to sales ratio | 568.91 | 10.11 | 385.99 | 56.34 | 141.91 | |
| POCF ratio | -7.5 | -6.67 | -5.69 | -2.36 | 0 | |
| PFCF ratio | -7.5 | -6.67 | -5.69 | -2.36 | 0 | |
| P/B Ratio | 1.6 | 1.05 | 1.07 | 0.88 | 0.71 | |
| PTB ratio | 1.6 | 1.05 | 1.07 | 0.88 | 0.71 | |
| EV to sales | 335.2 | 4.52 | 159.41 | 22.06 | 50.34 | |
| Enterprise value over EBITDA | -5.11 | -4.79 | -1.47 | -0.91 | -0.55 | |
| EV to operating cash flow | -4.42 | -2.99 | -2.35 | -0.92 | 0 | |
| EV to free cash flow | -4.42 | -2.98 | -2.35 | -0.92 | 0 | |
| Earnings yield | -0.14 | -0.15 | -0.32 | -0.54 | -0.75 | |
| Free cash flow yield | -0.13 | -0.15 | -0.18 | -0.42 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0.01 | 0.04 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0.03 | |
| Net debt to EBITDA | 3.56 | 5.91 | 2.1 | 1.42 | 1 | |
| Current ratio | 13.46 | 12.46 | 9.05 | 4.87 | 3.81 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.98 | 1.02 | 0.56 | 0.79 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 27.38 | 0.47 | 30.73 | 8.81 | 41.64 | |
| Research and developement to revenue | 41.07 | 1.54 | 81.04 | 17.13 | 53.25 | |
| Intangibles to total assets | 0.33 | 0.35 | 0.4 | 0.52 | 0.55 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0.48 | 0 | 3.69 | 0 | |
| Graham number | 17.33 | 12.41 | 11.97 | 8.16 | 7.2 | |
| ROIC | -0.19 | -0.11 | -0.31 | -0.39 | -0.45 | |
| Return on tangible assets | -0.29 | -0.2 | -0.48 | -0.75 | -0.88 | |
| Graham Net | 4.27 | 3.16 | 2.01 | 0.65 | 0.37 | |
| Working capital | 30M | 26.55M | 20.08M | 10.63M | 8.47M | |
| Tangible asset value | 27.55M | 23.62M | 17.2M | 7.23M | 5.16M | |
| Net current asset value | 26.91M | 23.07M | 16.72M | 6.82M | 4.8M | |
| Invested capital | 0 | 0 | 0 | 0.01 | 0.04 | |
| Average receivables | 81.21K | 2.34M | 2.35M | 226.84K | 425.77K | |
| Average payables | 1.39M | 1.54M | 1.59M | 1.74M | 1.56M | |
| Average inventory | 0.96 | -2.33M | -2.33M | -213.89K | -425.77K | |
| Days sales outstanding | 13.01 | 103.32 | 25.78 | 111.85 | 385.48 | |
| Days payables outstanding | 35.62 | 15.49 | 25.86 | 20.97 | 29.84 | |
| Days of inventory on hand | 0 | -67.24 | 0 | -6.53 | -7.24 | |
| Receivables turnover | 6.92 | 0.87 | 3.49 | 0.8 | 0.23 | |
| Payables turnover | 2.53 | 5.81 | 3.48 | 4.29 | 3.02 | |
| Inventory turnover | 5.53M | -1.34 | -44.61M | -13.78 | -12.43 | |
| ROE | -0.22 | -0.15 | -0.34 | -0.47 | -0.53 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
BNOX Frequently Asked Questions
What is Bionomics Limited stock symbol ?
Bionomics Limited is a AU stock , located in Eastwood of Sa and trading under the symbol BNOX
What is Bionomics Limited stock quote today ?
Bionomics Limited stock price is $0.9799 today.
Is Bionomics Limited stock public?
Yes, Bionomics Limited is a publicly traded company.
Company Profile
- Volume Average 192.45K
- Market Capitalization 10.64M
- Employee 8
- CEO Dr. Spyridon Papapetropoulos M.D., Ph.D.
- Headquarters Eastwood,SA,AU
- IPO Date 2021-12-16
-
Website
https://www.bionomics.com.au 
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.
